| Literature DB >> 33368842 |
Larissa H Moura-Castro1, Pablo Peña-Martínez1, Anders Castor2, Roman Galeev3, Jonas Larsson3, Marcus Järås1, Minjun Yang1, Kajsa Paulsson1.
Abstract
High hyperdiploid acute lymphoblastic leukemia (ALL) is one of the most common malignancies in children. The main driver event of this disease is a nonrandom aneuploidy consisting of gains of whole chromosomes but without overt evidence of chromosomal instability (CIN). Here, we investigated the frequency and severity of defective sister chromatid cohesion-a phenomenon related to CIN-in primary pediatric ALL. We found that a large proportion (86%) of hyperdiploid cases displayed aberrant cohesion, frequently severe, to compare with 49% of ETV6/RUNX1-positive ALL, which mostly displayed mild defects. In hyperdiploid ALL, cohesion defects were associated with increased chromosomal copy number heterogeneity, which could indicate increased CIN. Furthermore, cohesion defects correlated with RAD21 and NCAPG mRNA expression, suggesting a link to reduced cohesin and condensin levels in hyperdiploid ALL. Knockdown of RAD21 in an ALL cell line led to sister chromatid cohesion defects, aberrant mitoses, and increased heterogeneity in chromosomal copy numbers, similar to what was seen in primary hyperdiploid ALL. In summary, our study shows that aberrant sister chromatid cohesion is frequent but heterogeneous in pediatric high hyperdiploid ALL, ranging from mild to very severe defects, and possibly due to low cohesin or condensin levels. Cases with high levels of aberrant chromosome cohesion displayed increased chromosomal copy number heterogeneity, possibly indicative of increased CIN. These abnormalities may play a role in the clonal evolution of hyperdiploid pediatric ALL.Entities:
Keywords: acute lymphoblastic leukemia; aneuploidy; chromosomal instability; hyperdiploidy; sister chromatid cohesion
Mesh:
Substances:
Year: 2021 PMID: 33368842 PMCID: PMC8247877 DOI: 10.1002/gcc.22933
Source DB: PubMed Journal: Genes Chromosomes Cancer ISSN: 1045-2257 Impact factor: 5.006
FIGURE 1Analysis of sister chromatid cohesion, detected as primary constriction gaps (PCGs), in primary patient samples from high hyperdiploid and ETV6/RUNX1‐positive ALL cases. A, Metaphase from case HeH_3, classified as PCG I, where two chromosomes (arrows) displayed cohesion defects; B, metaphase from case HeH_40, classified as PCG II, where seven chromosomes (arrows) displayed cohesion defects; C, metaphase from case HeH_26, classified as PCG III, where 22 chromosomes (arrows) displayed cohesion defects; D, metaphase from case HeH_14, classified as PCG IV, that is, complete loss of cohesion. E, Incidence of cohesion defects, comparing high hyperdiploid and ETV6/RUNX1‐positive ALL cases: cohesion defects, shown as percentage of total cells presenting PCGs per case, where the boxes show the interquartile range and median (line) values, whiskers show minimum and maximum values in the cohort and outliers are shown as circles; F, classification of ETV6/RUNX1‐positive and high hyperdiploid cases according to the cohesion assay criteria, from “no PCG” to “PCG I‐IV”
FIGURE 2Copy number in HeH ALL primary patient cells with high PCG (primary constriction gaps) (HeH_4, HeH_14, HeH_18, HeH_40 and HeH_41) and low PCG (HeH_21, HeH_23, HeH_30, HeH_39 and HeH_42), analyzed by interphase fluorescence in situ hybridization for chromosomes X, 2, 3, 6, 10 and 21. A, Overall copy number of chromosome X, disomy expected; B, overall copy number of chromosome 2, disomy expected; C, overall copy number of chromosome 3, disomy expected; D, overall copy number of chromosome 6, trisomy expected; E, overall copy number of chromosome 10, trisomy expected; F, overall copy number of chromosome 21, tetrasomy expected; G, nucleus from HeH_42, showing disomy of chromosome X, disomy 3 and trisomy 10; H, nucleus from HeH_14, showing disomy X, monosomy 3 and trisomy 10; I, nucleus from HeH_40, showing trisomy X, disomy 3 and trisomy 10; J, nucleus from HeH_14, showing disomy X, trisomy 3 and trisomy 10; K, nucleus from HeH_14, showing monosomy 2,trisomy 6 and disomy 10; L, nucleus from HeH_41, showing trisomy 2, trisomy 6 and trisomy 10; M, nucleus from HeH_30, showing disomy 2, tetrasomy 6 and trisomy 10; N, nucleus from HeH_30, showing disomy 2, trisomy 6 and tetrasomy 10; O, nucleus from HeH_18, showing disomy 6, two copies of ETV6 (chromosome 12) and four copies of RUNX1 (chromosome 21); P, nucleus from HeH_40, showing tetrasomy 6, two copies of ETV6 and five copies of RUNX1; Q, nucleus from HeH_18, showing trisomy 6, three copies of chromosome ETV6 and five copies of RUNX1; R, nucleus from HeH_40, showing trisomy 6, two copies of ETV6 and three copies of RUNX1
FIGURE 3Copy number in REH cells with low expression of RAD21 (RAD21‐KD cells) and controls, analyzed by interphase fluorescence in situ hybridization for chromosomes X, 2, 3 and 21. A, Overall copy number of chromosome X, monosomy expected; B, overall copy number of chromosome 21, trisomy expected; C, nucleus from replicate RAD21.1‐3, showing one copy of chromosome X and two copies of chromosome 21; D, nucleus from replicate RAD21.2‐3, showing two copies of chromosome X and three copies of chromosome 21; E, nucleus from replicate RAD21.2‐2, showing one copy of chromosome X and four copies of chromosome 21; F, nucleus from replicate RAD21.1‐3, showing one copy of chromosome X and five copies of chromosome 21; G, overall copy number of chromosome 2, disomy expected; H, overall copy number of chromosome 3, disomy expected; I, nucleus from replicate RAD21.2‐4, showing two copies of chromosome 2 and one copy of chromosome 3; J, nucleus from replicate RAD21.2‐5, showing one copy of chromosome 2 and three copies of chromosome 3; K, nucleus from replicate control 5, showing two copies of chromosome 2 and three copies of chromosome 3; L, nucleus from replicate control 5, showing two copies of chromosome 2 and two copies of chromosome 3